Navigation Links
New strategies work to put cancer on the firing line

Dr. Yukai He wants to put cancer in the bulls eye.

Cancer really comes from us, the Medical College of Georgia Cancer Center immunologist says of the scary reality that cancer cells are our own cells gone awry. That means our immune system doesnt always see cancer as a horrific invader.

Tumors and T cells, the cellular arm of the immune system and the main player in anti-tumor immunity, cohabitate for many years before the tumor grows, says Dr. He, who recently was named one of the first Georgia Research Alliance Distinguished Investigators, a new initiative to support outstanding young investigators.

The tumor is smart, he says, changing just enough to stay out of the line of fire.

He and collaborators at Memorial Sloan-Kettering Cancer Center in New York, the University of Chicago and now MCG are putting together a package they believe will place it dead center.

The researchers are packaging an antigen gene that will alert the immune system in a novel viral vector delivery system while quashing the bodys misguided efforts to protect a tumor.

The treatment could one day follow tumor surgery and chemotherapy in patients when recurrence is likely, says Dr. He, who came to MCG in August from the University of Pittsburgh. It also could work for persistent viral infections such as HIV and human papillomavirus, parasitic diseases such as malaria and bacterial infections such as tuberculosis.

It is antigens proteins on or in all cells that get the attention of the immune system. Dendritic cells present antigens to T cells so that the host immune system will be alerted.

Using animal models of melanoma, researchers at Sloan-Kettering are taking key antigens and modifying them just enough to get the attention of T cells but still result in an immune response that targets the cancer.

Dr. He is looking for the best way to deliver modified antigens, identifying which dendritic cells actually present the antigens to T cells, so he can use a delivery mechanism that also gets their attention. Hes using the lentivector, the backbone of HIV minus most of the genes, as the basic mode of transportation. The vector obviously good at getting in and surviving in the body will ideally help generate a potent, memorable immune response that eradicates cancer or an infection in the first place then leaves an immune army waiting should it return.

Vaccination is by far the most effective approach for preventing infectious diseases. These vaccines stimulate B cells to produce antibodies to neutralize targeted bugs. These conventional vaccines are generated by inactivating microbes or attenuating their virulence. For example, the Salk Polio vaccine, first used in the1950s, was made from dead virus, and the Sabin Polio vaccines were from the attenuated virus, in which the infectious part of the virus was inactivated. Scientists next took advantage of the B cells ability to produce antibodies by identifying the most prominent antigen expressed, cloning it and giving it to patients to impart immunity from future infections. Tradeoffs of this type vaccine include a potentially weak immune response since its not the whole virus, but that also means it cant cause disease.

However, some persistent viruses such as HIV and malignant tumor lack a single protein that would inspire sufficient neutralizing antibodies, prompting researchers such as Dr. He to turn to development of T cell vaccines. So far, the most effective and safest way of stimulating T-cell immunity is with recombinant viral vectors, including the lentivector Dr. He is using. Recombinant viral vectors, already under study in HIV vaccine clinical trials, appear safe and effective.

Another important difference from conventional vaccines is that tumor vaccines need to work where tumor growth is established. Tumors impede the work by not just flying under the radar screen but actually suppressing the immune response. Two of Dr. Hes MCG colleagues discovered one of those suppressive mechanisms.

Dr. Andrew Mellor, director of the Immunotherapy Center and Georgia Research Alliance Eminent Scholar in Immunogenetics, and Dr. David Munn, pediatric hematologist-oncologist, showed in work published in 1998 in Science that fetuses use the enzyme IDO indoleamine 2,3-dioxygenase to locally disable a pregnant womans immune system and avoid rejection. Subsequent studies demonstrated that tumors also use IDO for protection by activating regulatory T cells, which has a suppressive effect on the anti-tumor immune response. Hopefully our collaboration will enable a comprehensive treatment package that includes a T cell vaccine and an IDO inhibitor to optimize the therapeutic effect in cancer patients, Dr. He says.


Contact: Toni Baker
Medical College of Georgia  

Related medicine news :

1. A New Interactive Consumer Experience Highlighting Successful Weight Loss Strategies is Coming to a Mall Near You
2. New strategies with greater antitumorous efficacy
3. Eclipsys User Network Brings Eclipsys Clients Together to Share Outcome Improvement Strategies
4. Research suggests targeted treatment strategies for lupus
5. Free White Paper Details Hospital Strategies for Meeting Joint Commission Compliance Requirements in the Environment of Care
6. UCSF launches action tank to advance promising global health strategies
7. New Lancet Study: Tobacco Control Measures Are Effective and Affordable Strategies to Reduce Chronic Disease Deaths Globally
8. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
9. Survival differences by race most apparent in advanced stages of breast cancer
10. MRI finds breast cancer before it becomes dangerous
11. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
Post Your Comments:
Related Image:
New strategies work to put cancer on the firing line
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology: